157 related articles for article (PubMed ID: 20203472)
1. Clinical features and treatment outcomes of vitiligo from the patients' perspective: results of a national survey in Germany.
Radtke MA; Schäfer I; Gajur AI; Augustin M
Dermatology; 2010; 220(3):194-200. PubMed ID: 20203472
[TBL] [Abstract][Full Text] [Related]
2. Willingness-to-pay and quality of life in patients with vitiligo.
Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M
Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268
[TBL] [Abstract][Full Text] [Related]
3. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire.
Augustin M; Gajur AI; Reich C; Rustenbach SJ; Schaefer I
Dermatology; 2008; 217(2):101-6. PubMed ID: 18451647
[TBL] [Abstract][Full Text] [Related]
4. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
Radtke MA; Schäfer I; Blome C; Augustin M
Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
[TBL] [Abstract][Full Text] [Related]
5. Effect of vitiligo on self-reported health-related quality of life.
Ongenae K; Van Geel N; De Schepper S; Naeyaert JM
Br J Dermatol; 2005 Jun; 152(6):1165-72. PubMed ID: 15948977
[TBL] [Abstract][Full Text] [Related]
6. From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo.
Schallreuter KU; Krüger C; Würfel BA; Panske A; Wood JM
Int J Dermatol; 2008 Jul; 47(7):743-53. PubMed ID: 18613887
[TBL] [Abstract][Full Text] [Related]
7. Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics.
Nicolaidou E; Antoniou C; Miniati A; Lagogianni E; Matekovits A; Stratigos A; Katsambas A
J Am Acad Dermatol; 2012 Jun; 66(6):954-8. PubMed ID: 21982634
[TBL] [Abstract][Full Text] [Related]
8. The burden of vitiligo: patient characteristics associated with quality of life.
Linthorst Homan MW; Spuls PI; de Korte J; Bos JD; Sprangers MA; van der Veen JP
J Am Acad Dermatol; 2009 Sep; 61(3):411-20. PubMed ID: 19577331
[TBL] [Abstract][Full Text] [Related]
9. What patients with vitiligo believe about their condition.
Firooz A; Bouzari N; Fallah N; Ghazisaidi B; Firoozabadi MR; Dowlati Y
Int J Dermatol; 2004 Nov; 43(11):811-4. PubMed ID: 15533062
[TBL] [Abstract][Full Text] [Related]
10. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre.
Kostopoulou P; Jouary T; Quintard B; Ezzedine K; Marques S; Boutchnei S; Taieb A
Br J Dermatol; 2009 Jul; 161(1):128-33. PubMed ID: 19298280
[TBL] [Abstract][Full Text] [Related]
11. [Long-term effects of PUVA therapy on Israeli patients with vitiligo].
Vussuki E; Ziv M; Rosenman D; David M
Harefuah; 2006 Jul; 145(7):483-5, 552, 551. PubMed ID: 16900734
[TBL] [Abstract][Full Text] [Related]
12. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
13. Clinical profiles of vitiligo in China: an analysis of 3742 patients.
Liu JB; Li M; Yang S; Gui JP; Wang HY; Du WH; Zhao XY; Ren YQ; Zhu YG; Zhang XJ
Clin Exp Dermatol; 2005 Jul; 30(4):327-31. PubMed ID: 15953059
[TBL] [Abstract][Full Text] [Related]
14. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool.
Blome C; Augustin M; Siepmann D; Phan NQ; Rustenbach SJ; Ständer S
Br J Dermatol; 2009 Nov; 161(5):1143-8. PubMed ID: 19857211
[TBL] [Abstract][Full Text] [Related]
15. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.
Lotti T; Buggiani G; Troiano M; Assad GB; Delescluse J; De Giorgi V; Hercogova J
Dermatol Ther; 2008 Jul; 21 Suppl 1():S20-6. PubMed ID: 18727812
[TBL] [Abstract][Full Text] [Related]
16. Measurement of patient-relevant benefits in the treatment of chronic hand eczema--a novel approach.
Blome C; Maares J; Diepgen T; Jeffrustenbach S; Augustin M
Contact Dermatitis; 2009 Jul; 61(1):39-45. PubMed ID: 19659963
[TBL] [Abstract][Full Text] [Related]
17. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo.
Scherschun L; Kim JJ; Lim HW
J Am Acad Dermatol; 2001 Jun; 44(6):999-1003. PubMed ID: 11369913
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo.
Agarwal S; Ramam M; Sharma VK; Khandpur S; Pal H; Pandey RM
Br J Dermatol; 2005 Jul; 153(1):163-6. PubMed ID: 16029343
[TBL] [Abstract][Full Text] [Related]
19. Management of vitiligo patients and attitude of dermatologists towards vitiligo.
Ongenae K; Van Geel N; De Schepper S; Vander Haeghen Y; Naeyaert JM
Eur J Dermatol; 2004; 14(3):177-81. PubMed ID: 15246945
[TBL] [Abstract][Full Text] [Related]
20. Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.
Augustin M; Reich K; Reich C; Purwins S; Jeff Rustenbach S; Schäfer I; Radtke M
J Dtsch Dermatol Ges; 2008 Aug; 6(8):640-5. PubMed ID: 18801145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
